Active, not recruitingPhase 2NCT04941287

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Studying Adenocarcinoma of the liver and intrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Nilofer S Azad, MD
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Intervention
Atezolizumab(biological)
Enrollment
57 enrolled
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (29)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04941287 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the liver and intrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the liver and intrahepatic biliary tract

← Back to all trials